Comparative Pharmacology
Head-to-head clinical analysis: CYCLOSET versus DOSTINEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CYCLOSET versus DOSTINEX.
CYCLOSET vs DOSTINEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cycloset (bromocriptine mesylate) is a dopamine D2 receptor agonist. It improves glycemic control in type 2 diabetes by resetting hypothalamic circadian rhythms, thereby reducing hepatic glucose production and increasing insulin sensitivity. It also suppresses the release of very low-density lipoprotein from the liver.
Cabergoline is a long-acting dopamine D2 receptor agonist that inhibits prolactin secretion by binding to D2 receptors on lactotroph cells in the anterior pituitary.
1.6 mg to 2.4 mg administered orally once daily at bedtime. Titrate by 0.8 mg every 2 weeks based on glycemic response and tolerability.
0.25 mg orally twice weekly, with a minimum of 2 days between doses; may increase by 0.25 mg twice weekly every 4 weeks up to a maximum of 1 mg twice weekly.
None Documented
None Documented
Terminal elimination half-life is 4–6 hours in patients with normal renal function; clinically, steady-state is reached within 24 hours.
The terminal elimination half-life is 63–69 hours in healthy volunteers and 79–115 hours in patients with hyperprolactinemia, allowing once- or twice-weekly dosing. The long half-life reflects slow dissociation from D2 receptors and enterohepatic recirculation.
Renal: ~90% (30% unchanged, rest as inactive metabolites); fecal: ~10%.
Cabergoline is extensively metabolized in the liver, primarily via CYP3A4. Elimination is predominantly fecal (60%) and renal (20%) as metabolites, with <4% as unchanged drug. Biliary excretion contributes to fecal elimination.
Category C
Category C
Dopamine Agonist / Antidiabetic
Dopamine Agonist